Q1 2026 saw 10.5% revenue growth and a 5.2% EBIT margin, driven by Rx and OTC segments, improved gross margin, and strong cash flow. Investments focused on scaling Varberg and launching apotea.no.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.